Latest Price of Talatumumab (Imdelltra) in 2025

Talatuzumab is a bispecific antibody drug developed by the American company Amgen. It targets DLL3 and CD3 molecules and activates T cells to kill abnormal cells. It is mainly used to treat extensive-stage small cell lung cancer that progresses after platinum-containing chemotherapy.

The latest price of talatumumab (Imdelltra) in 2025

Currently, talatumumab has not been launched in mainland China, nor has it been included in the medical insurance catalog. The original drug produced by Amgen in the United States will be the main source of global supply in 2025. The specifications are divided into 1 mg and 10 mg, and the prices are approximately US$6,102 and US$28,129 per box respectively.

Drug prices are greatly affected by research and development costs, production processes and market demand. The above prices are for reference only. As a targeted innovative drug, talatumumab requires high R&D investment and requires cold chain transportation and storage, which further increases the cost. There are no generic drugs yet on the market, and market competition is limited, making it difficult to lower prices in the short term.

Some online drug purchasing platforms can provide formal drug purchasing consultation services to qualified patients, but they must strictly follow the doctor's instructions and prescription process. Patients should verify the platform qualifications before purchasing to avoid the risks of informal channels.

How to use Talatumumab (Imdelltra)

Talatatumumab needs to be operated by medical staff in professional medical institutions. Before use, the patient's physical condition must be fully assessed and an individualized treatment plan must be formulated.

Dosing schedule and dose adjustment

The treatment adopts a stepwise increasing dosage method, with 1 mg used for the first time, increased to 10 mg on the 8th day, and 10 mg fixedly used every two weeks thereafter. The infusion time needs to be controlled within 1 hour, and it must be combined with dexamethasone pretreatment and normal saline hydration. If the medication is suspended due to adverse reactions, the dose needs to be readjusted according to the interval. If the medication is stopped for more than 28 days, the dosage needs to be restarted from 1 mg in increments.

Infusion preparation and operating specifications

Sterile water for injection must be used for drug reconstitution. Add 1.3 mL for 1 mg specification and 4.4 mL for 10 mg specification. After dilution, the infusion must be completed within 4 hours. The material of the infusion bag needs to be compatible with EVA or polyolefin to avoid using mismatched equipment.

The patient's vital signs need to be monitored throughout the infusion, and blood routine, liver and kidney function and other indicators need to be reviewed regularly during treatment to identify potential risks in a timely manner.

Precautions for talatumumab (Imdelltra)

The use of talatumumab must strictly follow the safety management process, focusing on preventing risks such as cytokine release syndrome and neurotoxicity.

Cytokine release syndrome and neurotoxicity

Cytokine release syndrome may cause high fever, hypotension and even organ failure. Grade 1 reactions require suspension of administration and antipyretic treatment, and grade 2 or higher reactions require hospitalization and monitoring with tocilizumab. Neurotoxic symptoms such as confusion or drowsiness require immediate discontinuation and evaluation, and use of hormonal treatment if necessary. All patients require continued monitoring for 24 hours after the first infusion.

Blood and infection risk control

Treatment may cause neutropenia or anemia, and blood routine testing needs to be done weekly. If the neutrophil count is lower than 1.0×10^9/L or fever occurs, administration must be suspended and anti-infective treatment must be given. Patients should avoid contact with sources of infection and seek medical treatment promptly when symptoms such as cough and painful urination occur.

Pregnant and lactating women are prohibited from using talatumumab. Patients of childbearing age must use strict contraception during treatment and within 2 months after stopping the drug. Elderly patients do not need to adjust the dosage, but increased monitoring is required. Patients with hepatic and renal insufficiency need to assess risks before use. Data for patients with moderate to severe injuries are limited, so it is recommended to use the drug with caution.